The top ten brands of veterinary drugs, founded in Germany in 1885, integrate human drugs/animal health/biopharmaceuticals, are committed to the research and development of human biopharmaceutical chemistry and animal health products, and focus on the field of vaccines and drugs for pigs/poultry/pets/cattle
Boehringer-Ingelheim is a pharmaceutical company dedicated to human biopharmaceutical, chemical and animal health products. The Human Pharmaceuticals segment is the company's largest segment, accounting for approximately 95% of sales. This includes prescription drugs and consumer health. It is one of the largest privately owned pharmaceutical companies in the world.The Boehringer Ingelheim Group is one of the world's top 20 leading pharmaceutical companies, with 145 locations and more than 44,000 employees worldwide. Boehringer Ingelheim is a highly R&D-driven company dedicated to the research, development, production and marketing of pharmaceutical products.
Boehringer Ingelheim's core business is pharmaceuticals for human use, including prescription drugs, autonomous health products and industrial customer businesses (biopharmaceuticals, pharmaceutical manufacturing and pharmaceutical chemicals). Boehringer Ingelheim's medicines have long been recognized as the benchmark for the treatment of respiratory, cardiovascular, and central nervous system diseases, as well as metabolic disorders and infectious diseases. The main research areas include immunology and oncology indications, and a number of active ingredients with therapeutic value potential have been developed.
Boehringer Ingelheim officially entered the Chinese market in 1994 and currently has a total investment of more than 200 million euros in China, with the company's management headquarters in Shanghai, with operations throughout the country and about 3,500 employees. Boehringer Ingelheim China has developed rapidly in recent years, including the three major business segments of human medicine, animal health and biopharmaceutical, which have developed in tandem and promoted the company's sustainable growth.
Pharmaceuticals for human use
Boehringer Ingelheim China contributes to the development, production and marketing of innovative medicines that improve people's health and improve the quality of life of patients. Boehringer Ingelheim China's human medicine business covers important therapeutic areas such as respiratory, cardiometabolic, central nervous system, and oncology, and its products include innovative therapeutic drugs such as chronic obstructive pulmonary disease, hypertension, stroke, atrial fibrillation stroke prevention, Parkinson's disease, diabetes, and non-small cell lung cancer. In the future, the company will launch more than 10 innovative products in the fields of COPD, asthma, diabetes and idiopathic pulmonary fibrosis to meet the needs of Chinese patients.
Boehringer Ingelheim will continue to increase its investment in R&D in China, where demand has been factored into the company's global early R&D decisions, which will comprehensively accelerate the launch of innovative products in China. At the same time, China has also become an active contributor to global R&D. By the end of 2016, about 45 clinical studies had been conducted in China, involving nearly 30,000 patients in the fields of stroke prevention, respiratory, diabetes, and oncology.
Cross-Boundary Research (RBB), one of the pillars of the company's strategy, expands R&D opportunities by exploring and researching emerging science, new indications and new technologies to complement the company's core therapeutic areas. China and Asia are fast becoming innovation hubs for biomedical research, and Boehringer Ingelheim is actively exploring opportunities for cooperation with Chinese academic institutions, and has established strategic partnerships with well-known universities in China to carry out comprehensive cooperation and early-stage scientific research.
Animal health
With the completion of the global business swap between Boehringer Ingelheim and Sanofi, Merial officially became part of the Boehringer Ingelheim family on January 1, 2017. Two leading animal health companies have joined forces to form a business unit within Boehringer Ingelheim. The combined company will become the world's second-largest animal health company and the world's leading supplier of antiparasitic drugs and vaccines for economic animals and pets.
Boehringer Ingelheim's Animal Health business employs more than 10,000 people worldwide, products are present in more than 150 markets, and are present in 99 countries around the world. The combined company is a global leader in pet, pig and equine and veterinary public health, with a leading position in the poultry and cattle businesses. Boehringer Ingelheim is committed to improving animal health, advancing the industry and further improving human and animal health.
As a leading animal health company in China, the company has a broad presence in China, covering the entire value chain from R&D, production to sales. Boehringer Ingelheim's diverse product portfolio covers vaccines and pharmaceuticals for swine, poultry, pets and cattle. The company is currently the market leader in swine and poultry vaccines in China, and is also developing well in the pet and dairy business areas. The company has an animal health R&D center in Shanghai, which is the first R&D center established by a multinational pharmaceutical company in China focusing on animal protection products. The company's production bases in Nanchang and Nanjing mainly produce poultry vaccine products, which are used to prevent and treat various diseases infected with broilers and laying hens, and provide related immunization services. In Taizhou, Jiangsu Province, the animal vaccine production site under construction will become the leading animal vaccine production base in Asia, developing and manufacturing high-quality vaccine products for China and other Asian markets.
Boehringer Ingelheim is committed to providing customers with better innovative solutions and better services, thereby contributing to the improvement of food safety and animal welfare in China.
Biopharmaceuticals
As one of the world's largest biopharmaceutical manufacturers, Boehringer Ingelheim wants to be the first international provider of biopharmaceutical contract manufacturing solutions in China, providing a full range of services from process development to clinical trials and market product supply for customers in China and around the world. Boehringer Ingelheim's biopharmaceutical manufacturing facility in China was officially opened in May 2017. As the first and only biopharmaceutical base with international standards established by a multinational pharmaceutical company in China, the site is an important milestone in the global strategic layout of Boehringer Ingelheim's biopharmaceutical business, with an investment of more than 70 million euros in the first phase.
As a "key lever point" to accelerate the R&D and transformation of biopharmaceutical technology, the innovative model of biopharmaceutical contract manufacturing can turn the "production bottleneck" in the original biopharmaceutical industry chain into a "service platform", helping the industrialization and value maximization of new drugs under development. In February 2016, Boehringer Ingelheim was selected as one of the "first pilot companies to carry out biopharmaceutical contract manufacturing in China". As a leader in the field of biopharmaceutical CMO, Boehringer Ingelheim will further promote the development of China's biopharmaceutical manufacturing industry, enhance the international competitiveness of China's biopharmaceutical industry, and promote the clinical research and marketing of innovative drugs in China, thereby supporting the accelerated development of China's biotechnology industry. The company's advanced production platform and management system and global biopharmaceutical network will promote Chinese enterprises to enter the international market for biotechnology drugs. At the same time, multinational pharmaceutical companies can also use the "bridge" of Boehringer Ingelheim China Biopharmaceutical Base to quickly enter the Chinese market.
